The future of AI regulation in drug development: a comparative analysis
Journal of Law and the Biosciences · 11.07.2025 · 12 (2)
DOI: 10.1093/jlb/lsaf028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Law and the Biosciences, online erschienen am 07.11.2025. Verfasst von Gabriela Lenarczyk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Studies in Bioscience Innovation Law, Faculty of Law, University of Copenhagen, Karen Blixens Plads 16, 2300 Copenhagen, Denmark. Die Arbeit wurde bisher 41-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation.
Abstract (Originalsprache)
As artificial intelligence (AI) transforms drug development, regulatory frameworks are evolving to oversee its implementation, particularly at the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This paper makes three contributions to understanding emerging regulatory approaches. First, we offer a comparative analysis of how these agencies have responded to AI-driven advances, incorporating new US executive orders and the European Union (EU)’s AI Act. Second, we propose a novel analytical framework to understand regulatory divergence: the FDA’s flexible, dialog-driven model contrasts with the EMA’s structured, risk-tiered approach, reflecting broader institutional and political-economic differences. While the former encourages innovation via individualized assessment, it can create uncertainty about general expectations; by contrast, the EMA’s clearer requirements may slow early-stage AI adoption but provide more predictable paths to market. Third, we examine whether AI applications—spanning target identification, generative chemistry, and clinical trial ‘digital twins’—are mature enough for standardized regulation, particularly amid shifting US policies and the EU’s structured oversight regime. Our analysis reveals patterns of convergence on risk-based principles but persistent transatlantic implementation differences, compounded by diminished US engagement in international cooperation. We conclude that heightened regulatory uncertainty in the USA under a new administration’s ‘America First’ stance and more stable, formalized rules in Europe both pose opportunities and challenges to AI-driven innovation in drug development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Advanced Studies in Bioscience Innovation Law, Faculty of Law, University of Copenhagen, Karen Blixens Plads 16, 2300 Copenhagen, Denmark.
- University of Michigan Law School, 625 S State St, Ann Arbor, MI 48109, USA.
- Duke University School of Law, 210 Science Dr, Durham, NC 27708, USA.
ORCID-Profile: Gabriela Lenarczyk, Timo Minssen
Förderung
- Novo Nordisk Foundation
Zitieren
APA
Lenarczyk, G., Minssen, T., Price, N., & Rai, A. (2025). The future of AI regulation in drug development: a comparative analysis. Journal of Law and the Biosciences, 12(2). https://doi.org/10.1093/jlb/lsaf028
Vancouver
Lenarczyk G, Minssen T, Price N, Rai A. The future of AI regulation in drug development: a comparative analysis. Journal of Law and the Biosciences. 2025;12(2). doi:10.1093/jlb/lsaf028
BibTeX
@article{Lenarczyk2025,
author = {Lenarczyk, Gabriela and Minssen, Timo and Price, Nicholson and Rai, Arti},
title = {The future of AI regulation in drug development: a comparative analysis},
journal = {Journal of Law and the Biosciences},
year = {2025},
volume = {12},
number = {2},
doi = {10.1093/jlb/lsaf028}
}
EUVIMED